TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03965039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dipotassium oxalate toothpaste
Description: Experimental dipotassium oxalate (3%) toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stannous fluoride toothpaste
Description: Marketed stannous fluoride (0.454%) toothpaste
Study: NCT03206112

Intervention type: OTHER
Intervention: PAS25
Description: We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.

Intervention type: OTHER
Intervention: PAS25
Description: We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.

Intervention type: OTHER
Intervention: PAS10
Description: We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles. TBS is a special form of

Intervention type: OTHER
Intervention: PAS10
Description: We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles. TBS is a special form of

Intervention type: OTHER
Intervention: PAS25-cTBS150
Description: We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.

Intervention type: OTHER
Intervention: PAS25-cTBS150
Description: We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
Study: NCT01998880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
Study: NCT03358654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells from umbilical cord
Description: inject mesenchymal stem cells from umbilical cord，and the patients will be followed up at 1, 2, 3, and 6 months after the injection.
Study: NCT01149343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2302025A, different formulations
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2302025A, different formulations
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2302025A, different formulations
Description: Intramuscular administration
Study: NCT02752230

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy
Study: NCT03941067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-event massage
Description: Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands
Study: NCT01149343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2302025A, different formulations
Description: Intramuscular administration
Study: NCT03012334

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator based on treatment sequence in 5-way crossover
Study: NCT00325143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib
Description: 1 intramuscular injection (3rd study vaccine dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine
Description: 3 intramuscular injections (1st, 2nd and 4th vaccine dose)
Study: NCT04194879

Intervention type: DIAGNOSTIC_TEST
Intervention: multi-target FIT-DNA analysis
Description: ColoClear® is intended for use as an adjunctive screening test for the detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It has the potential of increasing the sensitivity of detecting CRC as compared to FOBT or faecal immunochemical test (FIT), which detects the presence of hemoglobin in stool alone. A positive result may indicate the presence of colorectal cancer or pre-malignant colorectal neoplasia. ColoClear® is not intended as a replacement for diagnostic colonoscopy. A positive result in ColoClear®, as with any screening test, should be followed by colonoscopy. ColoClear® is intended for colorectal cancer screening in average risk individuals: adults of either sex, 40 years or older, who are at high risk for colorectal cancer.
Study: NCT01711541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT03674983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional Economic Incentive (CEI)
Description: If hair testing shows that a participant has taken PrEP pills about 5-7 times in the previous week, he will receive a grade A; if he has taken PrEP pills about 3-4 times in the previous week he will receive a grade B; and if he has taken PrEP pills only 2 times or less, he will receive a grade C. For those in the CEI group, if participant gets an A, he receives two additional prizes; if he gets a B, he receives one additional prize; and if he gets a C, he receives no additional prizes.
Study: NCT03645538

Intervention type: OTHER
Intervention: Parkinson's disease patients
Description: The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG.

Intervention type: OTHER
Intervention: No drug
Description: The neurophysiological evaluation in healthy subjects will be conducted by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG.
Study: NCT00497900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Daily vitamin D (cholecalciferol) tablets and rocaltrol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Daily vitamin D (cholecalciferol) tablets and rocaltrol
Study: NCT03965039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate toothpaste
Description: Marketed potassium nitrate (5%) toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium monofluorophosphate toothpaste
Description: Marketed sodium monofluorophosphate (0.76%) toothpaste
Study: NCT01711541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT02591888

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
Study: NCT01596530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug-AZD8931
Description: Active drug for biological activity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug-Placebo
Description: Placebo comparator for biological activity comparison
Study: NCT03385499

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood additional samples
Description: additional samples of mother's blood and umbilical cord at delivery

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood additional samples
Description: additional samples of mother's blood and umbilical cord at delivery

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood additional samples
Description: additional samples of mother's blood and umbilical cord at delivery
Study: NCT03874351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial direct current stimulation (tDCS)
Description: Active tDCS: transcranial direct current stimulation at intensity 1.5mA for 20 minutes per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.~Sham tDCS: transcranial direct current stimulation at intensity 1.5mA for 30seconds followed by 0 mA current for remaining time of the 20-minute intervention per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non-invasive transcranial direct current stimulation (tDCS)
Description: Active tDCS: transcranial direct current stimulation at intensity 1.5mA for 20 minutes per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.~Sham tDCS: transcranial direct current stimulation at intensity 1.5mA for 30seconds followed by 0 mA current for remaining time of the 20-minute intervention per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.
Study: NCT03036423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online video education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized mental exercises
Study: NCT04238572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction device
Description: Evaluate the impact of an audiovisual distraction device on the peroperative opioid consumption

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia nociception index
Description: ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia nociception index
Description: ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement
Study: NCT02972112

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: novel cognitive behavioral protocol for the treatment of tokophobia

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: standard birth preparation sessions.
Study: NCT02999100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH Oxytocin
Description: Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH Oxytocin
Description: Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Oxytocin
Description: Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Oxytocin
Description: Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROTAHALER
Description: ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROTAHALER
Description: ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
Study: NCT04925518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop Mechanical Ventilation
Description: Closed loop ventilation mode (Intellivent-ASV+®). Intellivent-ASV+® was initiated by activating the controllers for minute volume, PEEP (range 5 to 18 cmH2O) and fraction of inspired oxygen (FiO2) (range 21 to 100 %). The target shift ranges for CO2-management were set between -2.5 and +2.5 kPa, and for O2-management between -2 and +2 %.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Mechanical Ventilation
Description: Mechanical ventilation with a conventional mode, usually either biphasic positive airway pressure ventilation (DuoPAP®) or adaptive support ventilation (ASV®)
Study: NCT03490435

Intervention type: DIAGNOSTIC_TEST
Intervention: Tests for diagnosis of intestinal parasitic diseases
Description: Feces testing:~1. fresh fecal samples will be used to preparing direct (saline and iodine wet) mounts using supplementary techniques (flotation, sedimentation), as well as temporary mounts (hematoxylin and trichrome staining). Other technique of fresh fecal samples examination will be ParaSys™~2. A non-preserved stool samples will be stored below -20°C. Defrosted fecal specimen will be subjected to enzyme-linked immunosorbent assays (ELISA) - Giardia antigen test (coproantigens)
Study: NCT03097029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancreatic Enzyme
Description: All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
Study: NCT03059472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1 (Intervention)
Description: The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2 (Delayed intervention)
Description: The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network.
Study: NCT03678584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Supplemented with Chaetoglobosin A
Description: A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate
Study: NCT05008068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin with PRF at site of osteotome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin with PRF at site of osteotome
Study: NCT00615797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: intravenous immunoglobulin 2g/kg total given over 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard interventions penicillin VK and haloperidol
Description: Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
Study: NCT04938362

Intervention type: OTHER
Intervention: FDG-PET
Description: \[18F\]Deoxyglucose-positron emission tomography at 0-10 years after brain abscess

Intervention type: OTHER
Intervention: FDG-PET
Description: \[18F\]Deoxyglucose-positron emission tomography at 0-10 years after brain abscess

Intervention type: OTHER
Intervention: EEG
Description: Electroencephalography (EEG) at 0-10 years after brain abscess
Study: NCT01344174

Intervention type: DRUG
Group type: OTHER
Intervention: 5 days dexamethasone therapy
Description: dexamethasone 10mg, intravenously, po daily for the first 5 days
Study: NCT03185442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency
Description: Pulsed Radiofrequency is performed if the sensory threshold is below 0.5 volts, the PRF consists of 380 pulses
Study: NCT04938362

Intervention type: OTHER
Intervention: EEG
Description: Electroencephalography (EEG) at 0-10 years after brain abscess
Study: NCT02436733

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pleurectomy/decortication
Description: Lung sparing procedures consist of the resection of the pleura without removing the lung

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pleurectomy/decortication
Description: Lung sparing procedures consist of the resection of the pleura without removing the lung
Study: NCT01711528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study: NCT02436733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/Cisplatin
Description: On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
Study: NCT01499719

Intervention type: BEHAVIORAL
Intervention: Checklist introduction / Pause
Description: Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
Study: NCT01010854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPA FEC100
Description: oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
Study: NCT01441791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung protective strategy ventilation
Description: Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
Study: NCT01688635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US Approved Lantus
Description: Administered subcutaneously
Study: NCT00939939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: sitagliptin 100 mg/d for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: glimepiride 1 mg/d for 10 weeks
Study: NCT03103880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreatheSmart
Description: BreatheSmart is a comprehensive asthma monitoring system that combines a medical device and mobile application that are designed for use with Apple and Android mobile devices. The medical device connects to the mobile application using Bluetooth to facilitate the collection of controlled medication adherence, rescue medication usage, and asthma control.
Study: NCT00861588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoflavones (Soylife 25)
Description: 40mg of soy isoflavones capsule (once daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starch placebo
Study: NCT02178072

Intervention type: DRUG
Group type: OTHER
Intervention: 5-Azacitadine

Intervention type: DRUG
Group type: OTHER
Intervention: 5-Azacitadine
Study: NCT02131545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg gel applied topically
Description: Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg tablet by mouth
Description: Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg rectal suppository
Description: Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg gel applied topically
Description: Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours